A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Ulcerative Colitis

Brief description of study

The primary objective of this study is to observe the long-term safety of filgotinib in subjects who have completed or met protocol specified efficacy discontinuation criteria in a prior Gilead-Sponsored filgotinib treatment study in UC. The secondary objective of this study is to evaluate the effect of filgotinib on partial Mayo Clinic Score and to evaluate health-related quality of life. This is a long-term extension study. Some people in this study will receive open-label drug and some will receive double-blind drug. Open-label means you and your study doctor will know what study drug you will be taking. Double-blind means you and your study doctor will not know what study drug you will be taking.


Clinical Study Identifier: s18-00102
ClinicalTrials.gov Identifier: NCT02914535
Principal Investigator: Blanche Fung Liu
Currently Recruiting

Contact the research team to learn more about this study.


By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.